Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome
Yıl: 2022 Cilt: 26 Sayı: 3 Sayfa Aralığı: 181 - 183 Metin Dili: İngilizce DOI: 10.5152/tjem.2022.22012 İndeks Tarihi: 25-09-2022
Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome
Öz: Denosumab is a human-derived monoclonal immunoglobulin G2 antibody against the receptor activator of nuclear factor kappa B ligand, inhibiting the differentiation and function of osteoclast precursor cells by its antiosteoclastic action. Denosumab is approved for postmenopausal, glucocorti coid-induced, and male osteoporozis with high risk of fracture. The use of denosumab has increased in recent years. While new medications continue to be developed, the number of agents causing drug-induced vasculitis is expected to increase. It may be a good strategy to identify risk factors for vasculitis development and look for these factors before drug administration. Here, we present a rare complication of denosumab, urticarial vasculitis, after the first denosumab injection in an osteopo rotic woman diagnosed with Cushing’s syndrome.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
- 1. Kaltsas G, Manetti L, Grossman AB. Osteoporosis in Cushing’s syndrome. Front Horm Res. 2002;30:60-72. [CrossRef]
- 2. Rahaman SH, Jyotsna VP, Kandasamy D, Shreenivas V, Gupta N, Tandon N. Bone health in patients with Cushing’s syndrome. Indian J Endocrinol Metab. 2018;22(6):766-769. [CrossRef]
- 3. Di Somma C, Pivonello R, Loche S, et al. Effect of 2 years of cortisol nor malization on the impaired bone mass and turnover in adolescent and adult patients with Cushing’s disease: a prospective study. Clin Endo crinol (Oxf). 2003;58(3):302-308. [CrossRef]
- 4. Di Somma C, Colao A, Pivonello R, et al. Effectiveness of chronic treat ment with alendronate in the osteoporosis of Cushing’s disease. Clin Endocrinol (Oxf). 1998;48(5):655-662. [CrossRef]
- 5. Cummings SR, San Martin J, McClung MR. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–765.
- 6. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153-161. [CrossRef]
- 7. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmeno pausal women with low bone mineral density. N Engl J Med. 2006;354(8): 821-831. [CrossRef]
- 8. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93(6):2149-2157. [CrossRef]
- 9. Highlights of prescribing information. Available at: https://www. pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/pro lia/prolia_pi.pdf Accessed August 02, 2013.
- 10. Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transi tions in postmenopausal osteoporosis (the data-Switch study): exten sion of a randomized controlled trial. Lancet. 2015;386(9999):1147-1155. [CrossRef]
- 11. Rachner TD, Platzbecker U, Felsenberg D, Hofbauer LC. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy. Mayo Clin Proc. 2013;88(4):418-419. [CrossRef]
- 12. Cating-Cabral MT, Clarke BL. Denosumab and atypical femur fractures. Maturitas. 2013;76(1):1-2. [CrossRef]
- 13. Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical Trials Express: frac ture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo-controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99(7):2599-2607. [CrossRef]
- 14. Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P. Long term treatment of osteoporosis: safety and efficacy appraisal of deno sumab. Ther Clin Risk Manag. 2012;8:295-306. [CrossRef]
- 15. Rizzoli R, Reginster JY, Boonen S, et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteo porosis. Calcif Tissue Int. 2011;89(2):91-104. [CrossRef]
- 16. Toulis KA, Anastasilakis AD. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int. 2010;21(11):1963-1964. [CrossRef]
- 17. Bridgeman MB, Pathak R. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review. Clin Ther. 2011;33(11):1547- 1559. [CrossRef]
- 18. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012;66(12):1139-1146. [CrossRef]
- 19. Lecart MP, Reginster JY. Current options for the management of post menopausal osteoporosis. Expert Opin Pharmacother. 2011;12(16):2533- 2552. [CrossRef]
- 20. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ Safety-RelatedDrugLabelingChanges/ucm307218.htm. Accessed on August 20, 2015.
- 21. Sanchez A, Lozier M, Adkinson BC, Ilaiwy A. c-ANCA vasculitis after initia tion of denosumab. BMJ Case Rep. 2019;12(3):e228336. [CrossRef]
- 22. Fiszenson-Albala F, Auzerie V, Mahe E, et al. A 6-month prospective sur vey of cutaneous drug reactions in a hospital setting. Br J Dermatol. 2003;149(5):1018-1022. [CrossRef]
- 23. Botelho LF, Porro AM, Enokihara MM, Tomimori J. Adverse cutaneous drug reactions in a single quaternary referral hospital. Int J Dermatol. 2016;55(4):e198-e203. [CrossRef]
- 24. Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic cri teria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol. 2005;27(6):504-528. [CrossRef]
- 25. Radić M, Martinović Kaliterna D, Radić J. Drug-induced vasculitis: a clini cal and pathological review. Neth J Med. 2012;70(1):12-17.
| APA | imre e, Şeker A, Gogas Yavuz D (2022). Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome. , 181 - 183. 10.5152/tjem.2022.22012 |
| Chicago | imre eren,Şeker Aysun,Gogas Yavuz Dilek Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome. (2022): 181 - 183. 10.5152/tjem.2022.22012 |
| MLA | imre eren,Şeker Aysun,Gogas Yavuz Dilek Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome. , 2022, ss.181 - 183. 10.5152/tjem.2022.22012 |
| AMA | imre e,Şeker A,Gogas Yavuz D Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome. . 2022; 181 - 183. 10.5152/tjem.2022.22012 |
| Vancouver | imre e,Şeker A,Gogas Yavuz D Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome. . 2022; 181 - 183. 10.5152/tjem.2022.22012 |
| IEEE | imre e,Şeker A,Gogas Yavuz D "Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome." , ss.181 - 183, 2022. 10.5152/tjem.2022.22012 |
| ISNAD | imre, eren vd. "Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome". (2022), 181-183. https://doi.org/10.5152/tjem.2022.22012 |
| APA | imre e, Şeker A, Gogas Yavuz D (2022). Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome. Turkish Journal of Endocrinology and Metabolism, 26(3), 181 - 183. 10.5152/tjem.2022.22012 |
| Chicago | imre eren,Şeker Aysun,Gogas Yavuz Dilek Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome. Turkish Journal of Endocrinology and Metabolism 26, no.3 (2022): 181 - 183. 10.5152/tjem.2022.22012 |
| MLA | imre eren,Şeker Aysun,Gogas Yavuz Dilek Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome. Turkish Journal of Endocrinology and Metabolism, vol.26, no.3, 2022, ss.181 - 183. 10.5152/tjem.2022.22012 |
| AMA | imre e,Şeker A,Gogas Yavuz D Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome. Turkish Journal of Endocrinology and Metabolism. 2022; 26(3): 181 - 183. 10.5152/tjem.2022.22012 |
| Vancouver | imre e,Şeker A,Gogas Yavuz D Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome. Turkish Journal of Endocrinology and Metabolism. 2022; 26(3): 181 - 183. 10.5152/tjem.2022.22012 |
| IEEE | imre e,Şeker A,Gogas Yavuz D "Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome." Turkish Journal of Endocrinology and Metabolism, 26, ss.181 - 183, 2022. 10.5152/tjem.2022.22012 |
| ISNAD | imre, eren vd. "Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing’s Syndrome". Turkish Journal of Endocrinology and Metabolism 26/3 (2022), 181-183. https://doi.org/10.5152/tjem.2022.22012 |
